CONNECT WITH US
HealthTech

HealthTech

Abbott starts pivotal trial for mitral valve replacement device

MedTech Dive logo

Published on

Add as a preferred source on Google
Abbott starts pivotal trial for mitral valve replacement device

The study is testing a device that Abbott executives believe can expand the mitral valve market.

In July 2015, Abbott agreed to buy Tendyne for $225 million upfront and secured an option to acquire Cephea. Abbott CEO Robert Ford discussed that period on an earnings call in July, telling investors that companies were investing in mitral devices around 2015 believing that the market could be as big as the transcatheter aortic valve replacement sector.

A decade after the investments, Ford said, “We have the potential to actually make that a reality” with the Cephea valve. Ford’s forecast reflects the “incredibly positive things” he has heard about the transcatheter mitral valve replacement device.

Abbott is enrolling up to 585 people in the U.S., Canada and Europe to validate the device. The study is testing Cephea in people who either have moderate-to-severe mitral regurgitation or have mitral valves that no longer function properly because of a buildup of calcium at the base. A hospital in Wichita, Kansas, recently enrolled the first patient in the study.

Abbott sees the device as complementary to its transcatheter edge-to-edge repair device, MitraClip, and its other transcatheter mitral valve replacement system, Tendyne. MitraClip clips the leaflets of the mitral valve together. Tendyne delivers a self-expanding valve through a small incision in the chest.

The portfolio competes with mitral products from Edwards Lifesciences. Both companies sell devices for repairing and replacing mitral valves. Edwards sells its Sapien M3 system for transcatheter mitral valve replacement.



Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.